<DOC>
	<DOCNO>NCT01445691</DOCNO>
	<brief_summary>The purpose study determine safety utility 5-aminolevulinic acid ( ALA ) identify tumor surgery . 5-ALA FDA approve time . When investigator remove tumor brain , important remove tumor remove part normal brain . Sometimes difficult tumor look like normal brain . In brain tumor , 5-ALA make tumor glow red blue light . This may make easy doctor take tumor brain . The purpose study : - Make sure 5-ALA help doctor remove tumor . - Make sure 5-ALA cause side effect . If want participate study , doctor ( ) still best remove tumor brain . Whether join study change treatment brain tumor .</brief_summary>
	<brief_title>More Complete Removal Malignant Brain Tumors Fluorescence-Guided Surgery</brief_title>
	<detailed_description />
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Glioblastoma</mesh_term>
	<mesh_term>Glioma</mesh_term>
	<mesh_term>Brain Neoplasms</mesh_term>
	<mesh_term>Aminolevulinic Acid</mesh_term>
	<criteria>Subjects must clinically document primary brain tumor resection clinically indicate . Individuals suspect newly diagnose recurrent malignant glioma consider eligible study . The anticipated histology resection include : Anaplastic astrocytoma ( 10002224 ) , Anaplastic ependymoma , Anaplastic oligodendroglioma , Astrocytoma malignant NOS ( 10003572 ) , Glioblastoma ( 10018336 ) , Glioblastoma multiforme ( 10018337 ) , Gliosarcoma ( 10018340 ) . Prior therapy consideration protocol entry . Age 1880 . Eastern Cooperative Oncology Group ( ECOG ) performance status ≤ 2 ( Karnofsky ≥ 60 % ) . Life expectancy consideration protocol entry . Subjects must normal organ marrow function define : Leukocytes ≥ 3,000/mL Platelets ≥ 100,000/mL Total bilirubin upper limit normal Aspartate aminotransferase ( AST ) ( SGOT ) /alanine aminotransferase ( ALT ) ( SGPT ) ≤ 2.5 X institutional upper limit normal Creatinine upper limit normal OR Creatinine clearance ≥ 60 mL/min/1.73 m² patient creatinine level institutional normal The effect aminolevulinic acid ( ALA ) develop human fetus unknown . For reason , woman childbearing potential men must agree use adequate contraception ( hormonal barrier method birth control ; abstinence ) prior study entry duration study participation . Should woman become pregnant suspect pregnant participating study , inform treat physician immediately . A pregnancy test perform woman childbearing ability prior surgery . Women pregnant exclude trial . Ability understand willingness sign write informed consent document . Tumors involve midline , basal ganglion , brain stem assess MRI . Subjects may receive experimental therapy . History allergic reaction attribute compound similar chemical biologic composition aminolevulinic acid ( ALA ) . Patients refrain use potential phototoxic substance ( e.g . tetracycline , sulfonamide , fluoroquinolones , hypericin extract ) 72 hour . Personal family history porphyria . Uncontrolled intercurrent illness include , limited ongoing active infection , symptomatic congestive heart failure , unstable angina pectoris , cardiac arrhythmia , psychiatric illness/social situation would limit compliance study requirement . Pregnant woman exclude study aminolevulinic acid ( ALA ) unknown teratogenic abortifacient effect . Because unknown potential risk adverse event nurse infant secondary treatment mother aminolevulinic acid ( ALA ) , breastfeed discontinue mother treated aminolevulinic acid ( ALA ) . Women pregnant exclude trial . Prior history GI perforation , diverticulitis , and/or peptic ulcer disease . Inclusion woman minority : men woman member ethnic group eligible trial .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>Benign Neoplasms , Brain</keyword>
	<keyword>Brain Cancer</keyword>
	<keyword>Brain Neoplasms , Benign</keyword>
	<keyword>Brain Neoplasms , Malignant</keyword>
	<keyword>Brain Tumor , Primary</keyword>
	<keyword>Brain Tumor , Recurrent</keyword>
	<keyword>Brain Tumors</keyword>
	<keyword>Intracranial Neoplasms</keyword>
	<keyword>Neoplasms , Brain</keyword>
	<keyword>Neoplasms , Intracranial</keyword>
	<keyword>Primary Brain Neoplasms</keyword>
	<keyword>Primary Malignant Brain Neoplasms</keyword>
	<keyword>Primary Malignant Brain Tumors</keyword>
	<keyword>Gliomas</keyword>
	<keyword>Glioblastoma</keyword>
	<keyword>Surgery</keyword>
	<keyword>5-ALA</keyword>
	<keyword>Aminolevulinic acid</keyword>
	<keyword>Fluorescence</keyword>
</DOC>